Omeprazole

Major

Omeprazole Posaconazole Noxafil Explained Increased omeprazole exposure and reduced posaconazole exposure Details Omeprazole Primidone Mysoline Explained Reduced omeprazole exposure, reduced efficacy of omeprazole, increased PHENobarbital exposure and an increased risk of PHENobarbit... Details Omeprazole Relacorilant Lifyorli Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Omeprazole Rifampin Rifadin Explained Reduced omeprazole exposure Details Omeprazole Rilzabrutinib Wayrilz Explained Reduced rilzabrutinib exposure, reduced efficacy of rilzabrutinib, an increased omeprazole exposure and an increased risk of omepr... Details Omeprazole Ritonavir Norvir Explained Decreased omeprazole exposure Details Omeprazole Saquinavir Explained Increased saquinavir exposure Details Omeprazole Secretin Human Chirhostim Explained False positive secretin stimulation test results Details Omeprazole Selpercatinib Retevmo Explained Reduced selpercatinib exposure and reduced anti-tumor activity Details Omeprazole Sotorasib Lumakras Explained Reduced sotorasib exposure and anti-tumor activity Details Omeprazole Sparsentan Filspari Explained Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Omeprazole St John's Wort Explained Reduced omeprazole exposure Details Omeprazole Sunitinib Sutent Explained Reduction in sunitinib bioavailability Details Omeprazole Tacrolimus Astagraf Explained Increased tacrolimus exposure and an increased risk of toxicity Details Omeprazole Taletrectinib Ibtrozi Explained Reduced taletrectinib exposure and reduced efficacy of taletrectinib Details Omeprazole Tazemetostat Tazverik Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Omeprazole Velpatasvir Explained Decreased velpatasvir exposure Details Omeprazole Vismodegib Erivedge Explained Reduced vismodegib systemic exposure Details Omeprazole Voriconazole Vfend Explained Increased omeprazole exposure an increased voriconazole exposure Details Omeprazole Warfarin Coumadin Explained Altered warfarin exposure and altered INR Details Omeprazole Ziftomenib Komzifti Explained Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Omeprazole Chromogranin A Measurement Explained A false positive diagnostic evaluation for neuroendocrine tumors Details Omeprazole Atezolizumab Injection Tecentriq Impaired efficacy of atezolizumab Details Omeprazole Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Omeprazole Cyanocobalamin Injection Berubigen® Reduced cyanocobalamin absorption Details Omeprazole Cyanocobalamin Nasal Gel Nascobal Reduced cyanocobalamin absorption Details Omeprazole Cyclosporine Injection Atopica Altered cycloSPORINE exposure and an increased omeprazole exposure Details Omeprazole Cyclosporine Ophthalmic Cequa Altered cycloSPORINE exposure and an increased omeprazole exposure Details Omeprazole Diazepam Nasal Spray Valtoco Increased diazePAM exposure Details Omeprazole Diazepam Rectal Diastat Increased diazePAM exposure Details Omeprazole Ketoconazole Topical Extina® Foam Reduced ketoconazole exposure, reduced efficacy of ketoconazole, increased omeprazole exposure and an increased risk of omeprazole... Details Omeprazole Letermovir Injection Prevymis Altered omeprazole exposure Details Omeprazole Methotrexate Injection Abitrexate® Increased methotrexate exposure and an increased risk of methotrexate toxicity Details Omeprazole Methylphenidate Transdermal Patch Daytrana Altered pharmacodynamic and changes in release profile of methylphenidate Details Omeprazole Nivolumab Injection Opdivo Reduced efficacy of nivolumab Details Omeprazole Octreotide Injection Bynfezia Decreased octreotide bioavailability Details

Moderate

Omeprazole Alprazolam Xanax Explained Benzodiazepine toxicity (CNS depression, ataxia, lethargy) Details Omeprazole Armodafinil Nuvigil Explained Increased omeprazole exposure Details Omeprazole Artemether Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Omeprazole Cenobamate Xcopri Explained Increased exposure to CYP2C19 substrates and/or increased risk of adverse effects Details